The main thrombolytic drug used for cerebral infarction is alteplase. The most commonly used drug for intravenous thrombolysis in cerebral infarction is alteplase, also known as recombinant human tissue-type fibrinolytic plasminogen activator. This drug belongs to the fibrinolytic drugs, when given intravenously, this drug shows a relatively inactive state in the circulatory system, and once it binds to fibrin, it is activated and induces the conversion of fibrinogen to fibrinolytic enzyme, leading to fibrin degradation and clot dissolution. There are clear contraindications and indications for thrombolytic therapy for acute cerebral infarction, such as a high risk of hemorrhage, high blood pressure, and onset of more than 6 hours are not suitable for thrombolytic therapy. Patients with acute cerebral infarction are advised to consult a physician in time, who will decide whether to perform thrombolytic therapy according to the specific situation.